Shortly after the market closed on June 30, Biogen Inc. and Exelixis Inc. confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos, PhD, taking the helm of the Big Biotech July 15. The move is counterintuitive, both for the commercial-stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.
Scangos, a scientist turned entrepreneur, is best known for making deals of all stripes at a biotech with experimental medicines....
